AI PRICE FORECAST
ABT Stock Forecast & AI Price Prediction
Abbott Laboratories · Healthcare · Medical Devices
ABT live signal snapshot
Shares of ABT were last at $109.29, down 1.06% on the day, trading 17.2% below its 52-week high of $132.03 and 33.3% above its 52-week low of $81.97. The model's verdict for ABT right now: HOLD (71% confidence). The technical signals aren't aligned enough for a directional call yet. The short-term averages line up bullishly, and the price is holding above its 50-day line. Its one-month projection is about $106.16, a -2.9% move from the last price.
ABT's 14-day RSI is 61.1 — healthy bullish momentum without being overextended. The MACD indicator sits over its signal line, and the histogram reading of 0.41 shows buying pressure building. Its 50-day average ($103.98) is holding 2.4% above the 200-day ($101.54), the pattern chartists call a golden cross.
26 Wall Street analysts covering ABT put the average price target at $118.91 (range $100.00–$130.00), implying 8.8% upside from the current price. The current recommendation trend leans bullish: 23 Buy/Strong Buy ratings vs 0 Sell/Strong Sell (and 5 Hold).
Live figures from real market data feeds, current as of the last site build. Open the interactive ABT dashboard for numbers updated throughout today's session.
About Abbott Laboratories
Abbott Laboratories (ABT) is a medical devices company in the healthcare sector, headquartered in Abbott Park, IL, United States. Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It has a market value of about $189.3 billion and roughly 122,000 full-time employees. With a beta of 0.54, the stock has historically moved less than the overall market.
ABT performance vs. the market
ABT is down 12.8% so far in 2026, behind the S&P 500 (+11.4%) and behind the healthcare sector fund XLV (+22.1%). Over the past 12 months the stock has lost 13.2%, 24.7 points worse than the S&P 500. The direction has flipped lately — +6.5% over the past month versus −1.8% across three.
| Period | ABT | Sector (XLV) | S&P 500 |
|---|---|---|---|
| 1 month | +6.5% | +11.4% | −2.3% |
| 3 months | −1.8% | +12.2% | −2.3% |
| Year to date | −12.8% | +22.1% | +11.4% |
| 1 year | −13.2% | +28.3% | +11.5% |
Abbott Laboratories financials at a glance
Abbott Laboratories's most recent quarter (ended Sep 30, 2026) brought in $13.0 billion of revenue and net income of $920 million (a 7.1% net margin). Revenue was up 14.5% from the same quarter a year earlier. The stock trades at a price-to-earnings ratio of 40.8 on trailing earnings of $2.68 per share. Trailing free cash flow was $6.1 billion, and total debt equals 61% of shareholders' equity.
| Quarter ended | Revenue | Net income |
|---|---|---|
| Sep 30, 2026 | $13.0B | $920M |
| Jun 30, 2026 | $12.6B | $928M |
| Mar 31, 2026 | $11.2B | $1.1B |
| Dec 31, 2025 | $11.5B | $1.8B |
ABT vs. its peers
ABT's −12.8% this year ranks ahead of 1 of the 5 big healthcare names below. The strongest of the group this year is Edwards Lifesciences (EW, +24.1%).
| Company | Price | YTD | P/E | AI verdict |
|---|---|---|---|---|
| Abbott Laboratories (ABT) | $109.29 | −12.8% | 40.8 | HOLD |
| Medtronic (MDT) | $101.61 | +5.8% | 25.0 | HOLD |
| Stryker (SYK) | $318.79 | −9.3% | 33.9 | HOLD |
| Boston Scientific (BSX) | $45.13 | −52.7% | 19.0 | HOLD |
| Edwards Lifesciences (EW) | $105.81 | +24.1% | 61.5 | BUY |
| GE HealthCare Technologies (GEHC) | $82.60 | +0.7% | 17.5 | BUY |
ABT stock: common questions
What is the ABT stock price target?
26 Wall Street analysts put the average 12-month target at $118.91, in a range of $100.00–$130.00, versus a recent price of $109.29. Stock Pulse 247's model projects about $106.16 over the next month.
Is ABT a buy right now?
Our AI model currently rates ABT a HOLD at 71% confidence. Among analysts, 23 rate it Buy or Strong Buy, 5 Hold and 0 Sell. Neither is personal advice — weigh them with your own research and risk tolerance.
How has ABT stock performed this year?
ABT is down 12.8% so far in 2026, behind the S&P 500 (+11.4%) and behind the healthcare sector fund XLV (+22.1%). Over the past 12 months the stock has lost 13.2%, 24.7 points worse than the S&P 500. The direction has flipped lately — +6.5% over the past month versus −1.8% across three.
What is ABT's 52-week high and low?
ABT has traded between $81.97 and $132.03 over the past 52 weeks; at $109.29 it is 17.2% below its 52-week high of $132.03 and 33.3% above its 52-week low of $81.97.
What sector is ABT in, and who are its peers?
ABT is in the healthcare sector (medical devices). Its largest peers on Stock Pulse 247 include Medtronic (MDT), Stryker (SYK), Boston Scientific (BSX), Edwards Lifesciences (EW).
How accurate is the ABT forecast?
It's a model estimate from price history, technical indicators and analyst targets, not a guarantee — no model predicts short-term moves reliably. Use it as one input alongside your own research.
How this works: the forecast combines ABT's price history, momentum indicators (RSI, MACD, moving averages), volatility and analyst targets into one estimate. It's a model, not a guarantee.